Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510029 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
A Phase 1 study of Arrhythmia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00510029 is a Phase 1 study of Arrhythmia that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 72 participants, below the 1,884-participant average among 16 other Arrhythmia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00510029, a Phase 1 study of Arrhythmia, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.
Conditions Studied
Interventions
- DRUG GAP-134
Study Locations (1)
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510029
The ClinicalTrials.gov registry entry for NCT00510029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,884-participant average among 16 other Arrhythmia trials with a reported enrollment target (96% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arrhythmia appearing as the primary indexed condition, and to 1 intervention - of which GAP-134 is the first listed.
NCT00510029 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00510029 about?
NCT00510029 is a clinical study titled "Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously". The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.
What is the current status of trial NCT00510029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2007-09. Estimated completion is 2008-01.
What conditions does trial NCT00510029 study?
This clinical trial studies the following conditions: Arrhythmia.
What interventions are being tested in trial NCT00510029?
The interventions under investigation include: GAP-134 (DRUG).
Who is sponsoring clinical trial NCT00510029?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510029 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
-
Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation
RECRUITING · NA
-
Aveir AR Coverage With Evidence Development (CED) Study
RECRUITING
-
Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.